Meeting of the Parliament 13 January 2026
Fulton MacGregor has anticipated what I was about to say. Sepiapterin—I hope that I have pronounced that correctly—is expected to be launched in the United Kingdom in late 2027.
Some points have been made on national guidance, on which I am happy to write to members, and on the home monitoring kits, which I understand are in a research phase to demonstrate their efficacy and overall value. The chief pharmaceutical officer will be discussing that issue in the meeting that she will be having next month.
Families such as those known to Fulton MacGregor and to others in the chamber and across Scotland show extraordinary resilience in their management of PKU day in, day out. I assure them that the Scottish Government remains deeply committed to improving outcomes and to making a real and meaningful difference in the lives of everyone living with PKU and other rare conditions in Scotland.